The Food and Drug Administration yesterday alerted health care providers and the public to an increased risk of heart-related death from a drug used to treat gout, a type of arthritis in adults. Preliminary results from a safety clinical trial of the drug febuxostat (Uloric) show an increased risk of heart-related death compared to the gout medicine allopurinol, FDA said. “Health care professionals should consider this safety information when deciding whether to prescribe or continue patients on febuxostat,” the agency said. Febuxostat drug labels already carry a warning about cardiovascular events because the drug showed a higher rate of heart-related problems in clinical trials conducted before approval. “We are continuing to evaluate this safety issue and will update the public when we have more information,” FDA said. “We urge health care professionals and patients to report side effects involving febuxostat or other medicines to the FDA MedWatch program.”

Related News Articles

Headline
As the nation celebrates National Nurses Week in the midst of the COVID-19 pandemic, nurses' commitment and strength is inspiring communities across the…
Headline
The American Organization for Nursing Leadership yesterday unveiled a new resource to provide nurse leaders with practical tips and effective strategies for…
Headline
This year was already designated as the International Year of the Nurse and the Midwife before our current pandemic re-emphasized nurses’ vital role in caring…
Blog
When the World Health Assembly designated 2020 as the International Year of the Nurse and the Midwife, they had no idea a pandemic would envelop the world the…
Insights and Analysis
Rising to the Nightingale Challenge: Empowering the Next Generation of Health Care Trailblazers Nurses are the engine of health care. There are more…
Headline
AHA and its American Organization for Nursing Leadership today voiced support for the Resolving Extended Limbo for Immigrant Employees and Families Act (S.…